STOCK TITAN

$300K CEO bridge loan supports Harvard Apparatus (OTCQB: HRGN)

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Harvard Apparatus Regenerative Technology, Inc. entered into a related-party bridge loan with its Chairman and CEO, Junli He, for $300,000, documented in a Bridge Note bearing a fixed 8% annual interest rate.

The principal and accrued interest are due on the earlier of the company’s next capital raise with at least $5,000,000 in gross proceeds or April 13, 2027. The Bridge Note includes optional conversion at the lender’s discretion, covenants, and customary events of default such as failure to pay amounts due or comply with its terms.

Positive

  • None.

Negative

  • None.
Item 1.02 Termination of a Material Definitive Agreement Business
A significant contract was terminated, which may affect business operations or revenue.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Bridge loan principal $300,000 Principal amount of Bridge Note with CEO Junli He
Interest rate 8% per year Fixed annual interest on Bridge Note
Capital raise trigger $5,000,000 gross proceeds Threshold for earlier repayment of Bridge Note
Final maturity date April 13, 2027 Latest due date for principal and accrued interest
Bridge Note financial
"as evidenced by a Bridge Note executed by the Company in favor of, and accepted by, the Lender"
emerging growth company regulatory
"405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
events of default financial
"provides for certain events of default including if the Company fails to pay when due any amount owed thereunder"
Events of default are specific breaches or failures listed in a loan, bond, or credit agreement that give lenders the right to act, such as demanding immediate repayment, raising interest rates, or taking secured assets. They matter to investors because triggering one is like setting off a financial alarm: it raises the chance of foreclosure, restructuring, or bankruptcy and can sharply reduce the value of a company’s stock or bonds and increase borrowing costs.
covenants financial
"The Bridge Note provides for optional conversion at the discretion of the Lender, contains covenants, and provides for certain events of default"
Covenants are rules written into loan or bond contracts that require a company to do or avoid certain things—like keeping debt below a set level or not selling key assets. They matter to investors because they protect lenders and influence a company’s flexibility: tight covenants can limit growth plans but lower default risk, while loose covenants give freedom but increase credit risk, similar to how household rules affect a family’s budget choices.
false 0001563665 0001563665 2026-04-13 2026-04-13
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): April 13, 2026
 
Harvard Apparatus Regenerative Technology, Inc.
(Exact name of registrant as specified in its charter)
 
Delaware
 
001-35853
 
45-5210462
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)
 
84 October Hill Road, Suite 11, Holliston, MA
 
01746
(Address of principal executive offices)
 
(Zip Code)
 
Registrant’s telephone number, including area code: (774) 233-7300
 
Biostage, Inc.
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
 
Trading Symbol(s)
 
Name of each exchange on which registered
Common Stock
 
HRGN
 
OTCQB
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 

 
Item 1.02.
Termination of a Material Definitive Agreement.
 
On April 13, 2026, Harvard Apparatus Regenerative Technology, Inc. (the “Company”) entered into a loan arrangement with Junli He, the Chairman and Chief Executive Officer of the Company (the “Lender”), pursuant to which the Lender has agreed to loan the Company an aggregate amount of $300,000 as evidenced by a Bridge Note executed by the Company in favor of, and accepted by, the Lender (the “Bridge Note”).
 
The Bridge Note accrued interest at an annual fixed rate of 8%, and the principal amount thereof will be due and payable in full, together with all accrued and unpaid interest thereon, on the earlier to occur of a) the closing date (or later date of capital being provided pertaining to such continued offering that the following threshold is tripped) of the Company’s next capital raise that includes gross proceeds of at least $5,000,000 or b) April 13, 2027. The Bridge Note provides for optional conversion at the discretion of the Lender, contains covenants, and provides for certain events of default including if the Company fails to pay when due any amount owed thereunder, fails to comply with any agreement, covenant, condition, provision or term contained therein and other customary events of default.
 
The foregoing description of the Bridge Note does not purport to be complete and is qualified in its entirety by reference to the full text of such document, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.
 
 
Item 9.01.
Financial Statements and Exhibits.
 
(d) Exhibits.
 
Exhibit
Number
 
Title
10.1
 
Bridge Note dated as of April 13, 2026, by Harvard Apparatus Regenerative Technology, Inc. in favor of Junli He.
104
 
Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 

 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 
HARVARD APPARATUS REGENERATIVE TECHNOLOGY, INC.
     
Date: April 15, 2026
By:
/s/ Joseph Damasio
   
Joseph Damasio
   
Chief Financial Officer
 
 
 

FAQ

What financing did Harvard Apparatus Regenerative Technology (HRGN) enter on April 13, 2026?

Harvard Apparatus Regenerative Technology entered a related-party bridge loan for $300,000 with its Chairman and CEO, Junli He. The loan is documented in a Bridge Note with fixed interest and specific repayment triggers.

What are the key terms of HRGN’s $300,000 Bridge Note with Junli He?

The Bridge Note has a principal amount of $300,000 and a fixed 8% annual interest rate. Principal and accrued interest are due upon a qualifying capital raise of at least $5,000,000 or on April 13, 2027, whichever occurs first.

When does the $300,000 Bridge Note for Harvard Apparatus Regenerative Technology mature?

The Bridge Note matures on the earlier of a capital raise that includes at least $5,000,000 in gross proceeds or April 13, 2027. At that time, all principal and accrued interest become fully due and payable.

Does the HRGN Bridge Note with the CEO include conversion features?

Yes. The Bridge Note provides for optional conversion at the discretion of the lender, Chairman and CEO Junli He. This allows the lender to convert amounts owed under the note instead of receiving only cash repayment.

What events of default are described in Harvard Apparatus Regenerative Technology’s Bridge Note?

The Bridge Note lists customary events of default, including failure to pay any amount when due and failure to comply with agreements, covenants, conditions, provisions, or terms in the note, along with other typical default provisions.

Who is the lender under Harvard Apparatus Regenerative Technology’s $300,000 Bridge Note?

The lender is Junli He, the company’s Chairman and Chief Executive Officer. The company executed the Bridge Note in his favor, making this a related-party financing between the issuer and its top executive.

Filing Exhibits & Attachments

5 documents